Collaborations

Holter-Derived Data and Outcome in the CHS.
PI Phyllis K. Stein, Ph.D. Ancillary study of both the Cardiovascular Health Study and the Sleep Heart Health Study. Sponsor, NHLBI.
Ongoing study of heart rate variability and heart rate patterns from both Holter recordings and sleep studies as predictors of cardiovascular outcomes.

Cardiac Risk Markers and Unremitting Depression in Acute Coronary Syndrome.
PI Robert Carney, PhD. Sponsor, NHLBI.
Study of the effect of treatment for depression on heart rate variability and other parameters in depressed acute coronary syndrome patients who have failed other anti-depressant treatments.

Heart Rate Variability in Adult Patients with Sickle Cell Anemia.
PI Joshua Field, MD.
Study of heart rate variability patterns in patients with sickle cell anemia, a population at high risk for sudden cardiac death.

Physical Frailty in Urban African Americans.
PI Victor Davila-Roman, MD. Sponsor, NHLBI.
Study of heart rate variability patterns in a cohort of elderly African Americans who are being followed to determine who develops frailty. Multiple other cardiovascular and psychological measurements are also being taken during the examination.

Association of Holter-Derived Measures and Risk of Atrial Fibrillation after Cardiac Surgery.
PI Phyllis K. Stein, PhD. Sponsor Barnes-Jewish Hospital Foundation.
Study to determine if Holter-based measurements obtained on the night before cardiac surgery identify patients at especially high risk of developing atrial fibrillation after surgery.

The VETSA Longitudinal Twin Study of Cognition and Aging.
PI William Kremen, PhD. Sponsor NIA.
Second round of a cohort study of mono- and dizygotic twins who served during the Viet Nam war. Purpose of the study is to identify factors that are associated with healthy aging or cognitive decline. Twin design permits study of both genetic and environmental factors.

Past collaborations

Omega-3 for Depression and Other Cardiac Risk Factors.
PI Robert Carney, PhD. Sponsor NHLBI.
Study to determine it treatment with omega-3 fatty acids in addition to standard anti-depressant therapy is more effective than anti-depressants alone in improving depression among cardiac patients.

Effects of Depression on Short-Term Recovery after MI (PASTRAMI).
PI Kenneth Freedland, PhD. Sponsor NHLBI.
Study to determine if clinical factors, including heart rate variability, are associated with changes in depression status in patients who were diagnosed as being depressed at the time of their heart attack.

Evaluation of Stress in Gulf War Veterans with CMI.
PI Melvin Blanchard, MD. Sponsor DOD.
Study to determine if there are differences in clinical measures, including heart rate variability, between Gulf War veterans who had chronic multi-symptom illness (Gulf War Illness) and those who do not. This study is the second examination of an existing cohort.

Depression, Sleep Disorders and Coronary Heart Disease.
PI Robert Carney, PhD. Sponsor NHLBI.
Study to determine if sleep apnea is more prevalent in depressed than in non-depressed patients with known cardiovascular disease and whether there are differences in heart rate variability both while awake and asleep between these groups.

Depression and Mortality Following Myocardial Infarction (ENRICHD HRV Sub-study).
PI Robert Carney, PhD. Sponsor NHLBI.
Study to determine if heart rate variability is different in depressed and non-depressed patients with a recent heart attack. Study also determined whether heart rate variability differences would explain the worse survival of depressed cardiac patients.

Depression and Coronary Heart Disease.
PI Robert Carney, PhD. Sponsor NHLBI.
Study to compare heart rate variability in depressed and non-depressed patients with known coronary artery disease and to determine what effect, if any, treatment of depression with cognitive behavioral therapy has on heart rate variability.

Depression and Heart Failure in the Elderly.
PI Kenneth Freedland, PhD. Sponsor NHLBI.
Study to compare heart rate variability in depressed and non-depressed hospitalized patients with heart failure and to determine if differences in heart rate variability predict differences in survival between groups.

Changes in Heart Rate Variability and Mortality in CAST.
PI Phyllis K. Stein, PhD. Sponsor NHLBI.
Study to determine if heart rate variability before therapy with drugs to reduce abnormal heart beats (ventricular arrhythmias) and/or the change in heart rate variability associated with treatment predict mortality among post-heart attack patients in the Cardiac Arrhythmia Suppression Trial.

Heart Rate Variability in Chronic Multi-Symptom Illness.
PI Daniel Clauw, MD. Sponsor NIH and DOD contracts.
Studies on the relationship between having chronic fatigue syndrome or fibromyalgia and heart rate variability in men and women. Also study of the effect of having fibromyalgia on heart rate variability in women.

Industry-sponsored studies

Validation of an Algorithm for Detecting Sleep-Disordered Breathing.
PI Yachuan Pu, PhD. Sponsor CardioNet, Inc.
Validation of an automated algorithm to detect sleep-disordered breathing from outpatient telemetry vs. manual overreading of heart rate patterns.

Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study.
PI Prakash Deedwania, MD.
Study of the effect of treatment with eplerenone on heart rate variability in patients with a heart attack who developed heart failure at the time of their heart attack. Also study of the relationship of measured Holter parameters at baseline and both cardiac and sudden death.

Effect of Compound MCC-135 on Heart Rate Variability in Stable CHF.
PI Phyllis K. Stein, PhD. Sponsor Takeda Pharmaceuticals.
Phase II study of the effect of a drug that raises cellular calcium levels on heart rate variability and other clinical parameters in stable outpatients with heart failure.

Effect of aggressive versus moderate lipid-lowering therapy on myocardial ischemia: the Study Assessing Goals in the Elderly (SAGE).
PI Prakash Deedwania, MD. Sponsor Pfizer Pharmaceuticals.
Study compares two different treatments for elevated cholesterol in older adults whose Holter recordings showed ST-depression, i.e., lack of blood flow to part of the heart. HRV Lab analyzed beat-to-beat files from previously-scanned recordings to see if either treatment was associated with changes in heart rate variability.

Relationship of Holter-Derived T-Wave Alternans to Sudden Cardiac Death in EPHESUS.
PI Phyllis K. Stein, PhD. Sponsor GE Medical Systems.
Study measure the degree of t-wave alternans (a variability in the shape of the t-wave of the ECG) in a matched set of people who died or died suddenly in EPHESUS (described above) and people who did not.

Relationship of Holter-Derived T-Wave Alternans to Sudden Cardiac Death in the Cardiovascular Health Study.
PI Phyllis K. Stein, PhD. Sponsor GE Medical Systems.
Study measure the degree of t-wave alternans (a variability in the shape of the t-wave of the ECG) in a matched set of older people who had sudden cardiac death in the Cardiovascular Health Study (described above) and people who did not.

Detection of Sleep Apnea Using Heart Rate Patterns.
PI Phyllis K. Stein, PhD. Sponsor DMS Holter.
Pilot study comparing heart rate pattern detection with results of clinical sleep studies.

Sleep Apnea Monitoring Using Sleep-Disordered Heart Rate.
PI Phyllis K. Stein, PhD. Sponsor Medtronic, Inc.
Pilot study of detection of sleep apnea from an implanted device.

Effect of Smoking Cessation Using Nicoderm Patchs on Heart Rate Variability in Normal Adults.
PI Phyllis K. Stein, PhD. Sponsor Pfizer Pharmaceutical.
Heart rate variability measured to determine the effect of the autonomic nervous system of normal smoking, of being on the 21 mg patch and of smoking cessation 3 months later.

Effect on HRV of Moricizine, Labetalol, Pindolol, Visken and Normodyne in Normal Adults.
PI Phyllis K. Stein, PhD. Sponsors DuPont Pharmaceuticals; Merck Pharmaceuticals; Rhone Poulenc Rorer; and Marion Merrell Dow, Inc.
Various studies comparing heart rate variability of different medications on placebo and on blinded active treatment in normal adults.